Glucagon-like peptide-1 receptor agonists for type 2 diabetes : A rational drug development
(2019) In Journal of Diabetes Investigation 10(2). p.196-201- Abstract
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia. GLP-1 was shown to target these defects, and after the discovery that dipeptidyl peptidase-4 inactivates native GLP-1, several different dipeptidyl peptidase-4-resistant GLP-1 receptor agonists have been developed. They are administered subcutaneously, but show differences in molecular structure, molecular size and pharmacokinetics, the latter allowing twice-daily, once-daily or once-weekly administration.... (More)
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia. GLP-1 was shown to target these defects, and after the discovery that dipeptidyl peptidase-4 inactivates native GLP-1, several different dipeptidyl peptidase-4-resistant GLP-1 receptor agonists have been developed. They are administered subcutaneously, but show differences in molecular structure, molecular size and pharmacokinetics, the latter allowing twice-daily, once-daily or once-weekly administration. They have been shown to be efficient in reducing both glycated hemoglobin and bodyweight, and to be safe and highly tolerable. Cardiovascular outcomes trials have shown them to be neutral or beneficial. GLP-1 receptor agonists are positioned as add-ons to metformin alone or in combination with oral agents in the clinical paradigm. They are also efficient when combined with insulin, and fixed dose combinations with long-acting insulin have been developed. Recent development includes a very long administration schedule and oral availability. The research from the first demonstration of the antidiabetic action of GLP-1 in the early 1990s to the enormously accumulated data today represents a successful and rational development, which has been characterized by focused perseverance to establish this therapy in the management of type 2 diabetes.
(Less)
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Glucagon-like peptide-1, Treatment, Type 2 diabetes
- in
- Journal of Diabetes Investigation
- volume
- 10
- issue
- 2
- pages
- 6 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:30099845
- scopus:85053465715
- ISSN
- 2040-1116
- DOI
- 10.1111/jdi.12911
- language
- English
- LU publication?
- yes
- id
- 1be87b5e-45d6-4ee0-9d32-b8d1586fb666
- date added to LUP
- 2018-10-22 10:41:10
- date last changed
- 2024-07-08 20:57:50
@article{1be87b5e-45d6-4ee0-9d32-b8d1586fb666,
abstract = {{<p>Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia. GLP-1 was shown to target these defects, and after the discovery that dipeptidyl peptidase-4 inactivates native GLP-1, several different dipeptidyl peptidase-4-resistant GLP-1 receptor agonists have been developed. They are administered subcutaneously, but show differences in molecular structure, molecular size and pharmacokinetics, the latter allowing twice-daily, once-daily or once-weekly administration. They have been shown to be efficient in reducing both glycated hemoglobin and bodyweight, and to be safe and highly tolerable. Cardiovascular outcomes trials have shown them to be neutral or beneficial. GLP-1 receptor agonists are positioned as add-ons to metformin alone or in combination with oral agents in the clinical paradigm. They are also efficient when combined with insulin, and fixed dose combinations with long-acting insulin have been developed. Recent development includes a very long administration schedule and oral availability. The research from the first demonstration of the antidiabetic action of GLP-1 in the early 1990s to the enormously accumulated data today represents a successful and rational development, which has been characterized by focused perseverance to establish this therapy in the management of type 2 diabetes.</p>}},
author = {{Ahrén, Bo}},
issn = {{2040-1116}},
keywords = {{Glucagon-like peptide-1; Treatment; Type 2 diabetes}},
language = {{eng}},
number = {{2}},
pages = {{196--201}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Diabetes Investigation}},
title = {{Glucagon-like peptide-1 receptor agonists for type 2 diabetes : A rational drug development}},
url = {{http://dx.doi.org/10.1111/jdi.12911}},
doi = {{10.1111/jdi.12911}},
volume = {{10}},
year = {{2019}},
}